Quilter Plc Sells 24,555 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Quilter Plc decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 22.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,263 shares of the biopharmaceutical company's stock after selling 24,555 shares during the quarter. Quilter Plc's holdings in Bristol Myers Squibb were worth $5,078,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in BMY. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb in the 4th quarter worth about $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $26,000. Global Wealth Strategies & Associates grew its stake in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares in the last quarter. Transce3nd LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $28,000. Finally, Fairway Wealth LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $46.68 on Friday. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1 year low of $39.35 and a 1 year high of $63.33. The company's 50-day moving average is $47.96 and its 200 day moving average is $54.02. The stock has a market capitalization of $95.01 billion, a P/E ratio of 17.48, a P/E/G ratio of 1.38 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm's revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the company posted ($4.40) earnings per share. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.31%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. UBS Group cut their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $58.00.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.09% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.